Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
Publishing timestamp: 2023-12-02 08:00:01
Summary
Pfizer has dropped its twice-daily version of an experimental weight loss pill due to high rates of adverse side effects in a clinical trial. This adds to the long list of scrapped obesity drugs, highlighting the difficulty in developing effective and safe treatments for weight loss. Other pharmaceutical companies have also faced challenges in this area, with many drugs being rejected or pulled from the market due to unintended side effects. Despite recent breakthrough medications, the path to treating obesity has been filled with failures.
Sentiment: NEGATIVE
Tickers: 4523.T-JP, PFE, ABT, NOVO.B-DK, LLY, SAN-FR,
Keywords: biotechnology, pfizer inc, business news, abbott laboratories, science, pharmaceuticals, eisai co ltd, business, sanofi sa, biotech and pharmaceuticals, health care industry, novo nordisk a/s, united states, eli lilly and co,
Source: https://www.cnbc.com/2023/12/02/pfizer-weight-loss-pill-joins-list-of-obesity-drug-flops.html